Journey Medical Corporation Expects Topline Results From The Phase 3 Clinical Trials Evaluating DFD-2 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10, 2023
Portfolio Pulse from Happy Mohamed
Journey Medical Corporation (NASDAQ:DERM) announced that it expects topline results from the Phase 3 clinical trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea to be announced the week of July 10, 2023. The trials are expected to support a New Drug Application submission in the United States and a Marketing Authorization Application in Europe. DFD-29 is being developed in collaboration with Dr. Reddy's Laboratories Ltd.
July 03, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Journey Medical's announcement of expected topline results from Phase 3 trials of DFD-29 could potentially impact its stock positively, as successful trials could lead to a new drug application.
The announcement of expected topline results from Phase 3 trials is a significant milestone for any pharmaceutical company. If the results are positive, it could lead to a new drug application, which could potentially increase Journey Medical's revenue and positively impact its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100